Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi® (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced data from multiple resmetirom abstracts presented at the European Association for the Study of the Liver’s International Liver Congress (EASL 2022), including a late-breaking presentation of data from the Phase 3 MAESTRO-NAFLD-1 study and three additional oral presentations from the resmetirom clinical development program.
Following the recent retirement of Jonathan Javitt in March, Robert Besthof, Head of Operations and Chief Commercial Officer, has taken over as interim chief executive officer of NRx Pharmaceuticals. He said there was a need for a CEO to be based in the U.S. alongside the rest of the team.
WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies USA
WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen’s WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy product to cancer patients.
University of Pennsylvania joins NFT frenzy to commemorate mRNA breakthrough and support medical research
The NFT will be auctioned by the British auction house Christie’s with the proceeds going to support research at Penn Medicine and the university.
Verismo Therapeutics, a recent University of Pennsylvania spin-out company behind the novel KIR-CAR platform technology for CAR T-cells, today announces that Penn and Verismo entered into a Sponsored Research Agreement (SRA). Under the SRA, Verismo is funding additional KIR-CAR T-cell focused preclinical research programs at Penn to advance new potential treatment options for solid tumor indications. The research funded under the SRA is expected to be conducted over four years, from 2021 to 2025, in the Penn laboratories of Michael C. Milone, MD, PhD, an associate professor of Pathology and Laboratory Medicine, and Donald L. Siegel, MD, PhD, a professor of Pathology and Laboratory Medicine.
As the pipeline for cell therapies grows, manufacturers and CDMOs are looking to get in on the action.
The Center for Breakthrough Medicines, a Pennsylvania-based CDMO, is partnering with Discovery Labs to accelerate plans to build the capacity to manufacture more than 10,000 patient therapies at their headquarters in King of Prussia, PA, a suburb of Philadelphia.
The planning has begun on the manufacturing suites and supporting infrastructure, and when completed the facility, according to CBM’s conservative calculations, the site will be able to produce around 10,000 batches of product per year in the space.
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the “2022 Best Places to Work.”
Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World￼
The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer.
or the third year in a row, Philly is trending upward on the Startup Genome’s Global Startup Ecosystem Report (GSER) report.
After ranking No. 28 on the org’s global list for best ecosystems for startups in 2021, Philadelphia lands at No. 27 in 2022. In 2020, Philly was ranked as the top “emerging” startup ecosystem in the US.
The cities are rated on a scale in six categories: performance, funding, connectedness, market reach, talent and knowledge. Startup Genome considered 300 ecosystems for this year’s list. Philly scored high for performance and market reach, middle of the road for talent and experience, and low for funding, connectedness and knowledge compared to other cities.